Clinical Trial

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.
Protocol Amendment History 3 changes
notable Primary completion pushed: 2031-04-01 -> 2031-06-01 2026-06-13
minor Completion pushed: 2036-04-01 -> 2036-06-01 2026-06-13
critical Recruitment opened 2026-05-27
Trial Details
NCT Number NCT07321912
Lead Sponsor Milton S. Hershey Medical Center
Collaborators: USWM, LLC (dba US WorldMeds)
Conditions Osteosarcoma, Ewing Sarcoma
Enrollment 406 participants
Start Date 2026-06-05
Primary Completion 2031-06-01 (estimated)
Study Completion 2036-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-09